Evidence map›Paper›PMID 29179874›Full record

ArticlePapillomavirus research (Amsterdam, Netherlands)2017

HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and Linear Array HPV Genotyping test in Australian cervical samples.

Alyssa M Cornall, Marin Poljak, Suzanne M Garland, Samuel Phillips, Dorothy A Machalek, Jeffrey H Tan, Michael A Quinn, Sepehr N Tabrizi

Abstract readComparative Study
In one paragraph

Article in Papillomavirus research (Amsterdam, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Identifying the Impact ofPathogens (Basel, Switzerland) · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alyssa M CornallRegional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville 3052, Victoria, Australia; Murdoch Childrens Research Institute, Parkville 3052, Victoria, Australia; Department of Obstetrics and Gynecology, University of Melbourne, Parkville 3052, Victoria, Australia. Electronic address: Alyssa.Cornall@mcri.edu.au.
Marin PoljakRegional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville 3052, Victoria, Australia; Murdoch Childrens Research Institute, Parkville 3052, Victoria, Australia. Electronic address: poljakm87@gmail.com.
Suzanne M GarlandRegional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville 3052, Victoria, Australia; Murdoch Childrens Research Institute, Parkville 3052, Victoria, Australia; Department of Obstetrics and Gynecology, University of Melbourne, Parkville 3052, Victoria, Australia. Electronic address: Suzanne.Garland@thewomens.org.au.
Samuel PhillipsRegional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville 3052, Victoria, Australia; Murdoch Childrens Research Institute, Parkville 3052, Victoria, Australia. Electronic address: Sam.Phillips@mcri.edu.au.
Dorothy A MachalekRegional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville 3052, Victoria, Australia; Murdoch Childrens Research Institute, Parkville 3052, Victoria, Australia. Electronic address: Dorothy.Machalek@mcri.edu.au.
Jeffrey H TanDepartment of Obstetrics and Gynecology, University of Melbourne, Parkville 3052, Victoria, Australia; Oncology and Dysplasia Unit, Royal Women's Hospital, Parkville 3052, Victoria, Australia. Electronic address: Jeff.Tan@thewomens.org.au.
Michael A QuinnDepartment of Obstetrics and Gynecology, University of Melbourne, Parkville 3052, Victoria, Australia; Oncology and Dysplasia Unit, Royal Women's Hospital, Parkville 3052, Victoria, Australia. Electronic address: QuinnM@ramsayhealth.com.au.
Sepehr N TabriziRegional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville 3052, Victoria, Australia; Murdoch Childrens Research Institute, Parkville 3052, Victoria, Australia; Department of Obstetrics and Gynecology, University of Melbourne, Parkville 3052, Victoria, Australia. Electronic address: Sepehr.Tabrizi@thewomens.org.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare human papillomavirus genotype-specific performance of two genotyping assays, Anyplex II HPV28 (Seegene) and EuroArray HPV (EuroImmun), with Linear Array HPV (Roche).

methodsDNA extracted from clinican-collected cervical brush specimens in PreservCyt medium (Hologic), from 403 women undergoing management for detected cytological abnormalities, was tested on the three assays. Genotype-specific agreement were assessed by Cohen's kappa statistic and Fisher's z-test of significance between proportions.

resultsAgreement between Linear Array and the other 2 assays was substantial to almost perfect (κ = 0.60 - 1.00) for most genotypes, and was almost perfect (κ = 0.81 - 0.98) for almost all high-risk genotypes. Linear Array overall detected most genotypes more frequently, however this was only statistically significant for HPV51 (EuroArray; p = 0.0497), HPV52 (Anyplex II; p = 0.039) and HPV61 (Anyplex II; p=0.047). EuroArray detected signficantly more HPV26 (p = 0.002) and Anyplex II detected more HPV42 (p = 0.035) than Linear Array. Each assay performed differently for HPV68 detection: EuroArray and LA were in moderate to substantial agreement with Anyplex II (κ = 0.46 and 0.62, respectively), but were in poor disagreement with each other (κ = -0.01).

conclusionsEuroArray and Anyplex II had similar sensitivity to Linear Array for most high-risk genotypes, with slightly lower sensitivity for HPV 51 or 52.

Indexed as

GenotypeAustraliaCervix UteriDNA, ViralFemaleGenotyping TechniquesHumansMolecular Diagnostic TechniquesPapillomaviridaePapillomavirus InfectionsPolymerase Chain ReactionReagent Kits, DiagnosticSensitivity and SpecificityDNA, ViralReagent Kits, DiagnosticAnyplex IICervixEuroArrayGenotypingHuman papillomavirusLinear Array

Identifiers

PMID29179874
PMCPMC5883236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.